Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Bardet-Biedl Syndrome
NCT07674290Phase 4Recruiting
- Sponsor
- Tom Hühne
- Start
- Jan 2023
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of setmelanotide in Bardet–Biedl syndrome (BBS) and Alström syndrome (ALMS), sponsored by Tom Hühne. Primary endpoints: Percent change in Body Mass Index z-score at 72 months, Impact on lipid profile at 72 months and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
setmelanotide
03
Conditions
Bardet–Biedl syndrome (BBS)Alström syndrome (ALMS)
Beyond the preview
Go deeper on NCT07674290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674290.